IP Library Granted Patent US 9,827,242
Granted Patent B2
US 9,827,242 · App. 14/994,939 · Granted Nov 28, 2017

Method of treatment for mental disorders

Inventors: Kazuhito Ikeda (Osaka, JP); Takeo Ishiyama (Osaka, JP)
Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
A61K31/496A61K9/0053A61K9/20A61K45/06A61K31/4035A61K31/428
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,827,242
App. No.
14/994,939
Granted
Nov 28, 2017
Kind
B2
Abstract

The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D 4 receptor agonist.

Claims (6)

1. A method for improving attention function in schizophrenia and/or bipolar disorder which comprises administering a pharmaceutical composition comprising, as the sole active ingredient a therapeutically effective amount of lurasidone or a pharmaceutically acceptable acid addition salt thereof to a mammal in need thereof.

2. The method of claim 1 wherein the pharmaceutical composition is a tablet, wherein lurasidone or a pharmaceutically acceptable acid addition salt thereof is lurasidone hydrochloride and wherein the tablet is orally administered in a dosage of 20 mg to 160 mg per day.

3. The method of claim 1 wherein the attention function is attention function in bipolar disorder.

4. The method of claim 1 wherein the attention function is attention function in schizophrenia.

5. The method of claim 1 wherein improving attention function is one or more selected from the group consisting of improving impairment in continuous concentration, improving diminished rapid-reaction and improving reduced activity.

6. A method for improving attention function in schizophrenia and/or bipolar disorder which comprises administering a therapeutically effective amount of lurasidone or a pharmaceutically acceptable acid addition salt thereof as the sole active ingredient to a mammal in need thereof, wherein improving attention function is improving reduced activity.

Assignments (1)
CHANGE OF NAME Recorded Nov 21, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 061972/0730 →
Priority Claims (1)
JP 2011-033453 · Feb 18, 2011 · national
Continuity (4)
Continuation 13555044 · Jul 20, 2012
Continuation 13113703 · May 23, 2011
Provisional Application 61411081 · Nov 8, 2010
Related Publication 20160193205A1 · Jul 7, 2016